Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria
NCT01570075 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2012-04-04
Summary
Hepatocellular carcinoma (HCC) is a common cancer, and it is the third commonest global cause of cancer-related death. With an increase in life-expectancy of the general population, the number of elderly with HCC is expected to increase. Current curative treatment options for HCC include: liver transplantation, liver resection (LR) and local ablation therapy. Liver transplantation is a good treatment for HCC within the Milan criteria (single HCC ≤ 5 cm or up to 3 nodules each \< 3 cm). As a consequence of the lack of liver donors, one relative contraindication for liver transplantation is age over 65 years, or the protocol requires elderly patients to have very good general health before they can be put on a transplant list. Transcatheter arterial chemoembolization (TACE) is used more commonly for the treatment of intermediate and advanced-staged HCC, while liver resection and local ablation therapy are used for early-staged HCC. Amongst the local ablative therapies, radiofrequency ablation (RFA) is most widely used. It has the advantage of minimally invasiveness, making it the first-line treatment for small HCC in patients with compromised liver function or associated severe medical conditions.
Elderly patients are more likely to have poor general conditions and associated medical diseases. RFA has the advantage of being less invasive and it causes less pain, less blood loss and earlier recovery than LR. On the other hand, incomplete ablation of HCC and tumor track seeding may happen. Several studies have demonstrated the safety of LR for elderly patients. There is no good evidence in the medical literature to support whether RFA or LR is a better treatment for elderly patients with HCC.
Conditions
Interventions
- PROCEDURE
-
HR
SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
- PROCEDURE
-
RFA
For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 65 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2014-07-31
- Completion
- 2015-07-31
Countries
- China
Study Locations
More Related Trials
-
RFA Versus SBRT for Recurrent Small HCC
NCT04047173 ·Status: COMPLETED ·Phase: PHASE3
-
No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma
NCT02830737 ·Status: UNKNOWN ·Phase: NA
-
Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma
NCT01713244 ·Status: UNKNOWN ·Phase: NA
-
Combined Treatment of RFA and Sorafenib on Recurrent HCC
NCT01470495 ·Status: UNKNOWN ·Phase: NA
-
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
NCT02187081 ·Status: UNKNOWN ·Phase: NA
-
Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC
NCT05433701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00557024 ·Status: UNKNOWN ·Phase: PHASE4
-
Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
NCT00554905 ·Status: UNKNOWN ·Phase: PHASE4
-
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
NCT00814242 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
NCT06462742 ·Status: RECRUITING
-
TACE-HAIC vs. HAIC for Potentially Resectable HCC
NCT03591705 ·Status: UNKNOWN ·Phase: NA
-
Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
NCT00479050 ·Status: COMPLETED ·Phase: PHASE1
-
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT01409499 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
NCT00730860 ·Status: UNKNOWN ·Phase: NA
-
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
NCT01833299 ·Status: COMPLETED ·Phase: PHASE3
-
Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
NCT03790059 ·Status: UNKNOWN ·Phase: NA
-
Impact of Hepatectomy on HCC Recurrence
NCT06390228 ·Status: COMPLETED
-
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
NCT01858207 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma
NCT03988998 ·Status: UNKNOWN ·Phase: PHASE3
-
Resection+Highly Purified CTL Versus Resection Alone for HCC
NCT02709070 ·Status: UNKNOWN ·Phase: PHASE3
-
AI Multitask Model for HCC Treatment
NCT07157085 ·Status: COMPLETED
-
Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation
NCT01340105 ·Status: COMPLETED ·Phase: NA
-
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430 ·Status: RECRUITING
-
The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma
NCT00720668 ·Status: UNKNOWN
-
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
NCT00556803 ·Status: UNKNOWN ·Phase: PHASE4